EUCTR2015-003701-42-IT进行中（未招募）1 期
An open-label, prospective, non-randomized, multicenter study to evaluate clear skin effect on health-related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque psoriasis treated with secukinumab 300 mg s.c. with or without previous exposure to systemic therapy - A study to evaluate clear skin effect in patients with plaque psoriasis.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •*Men or women aged at least 18 years at time of Screening.
- •*Moderate to severe plaque-type psoriasis diagnosed for at least 3 months prior to Screening and candidate for systemic therapy.
- •Other protocol defined inclusion criteria may apply. Please refer to the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1470
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 145
排除标准
- •*Forms of psoriasis other than moderate to severe plaque-type psoriasis, e.g. drug-induced psoriasis at Screening.
- •*Patients with previous treatment with any agent targeting interleukin (IL)-17 directly or IL-17 receptor A (e.g. secukinumab, ixekizumab, or brodalumab).
- •*Pregnant or nursing (lactating) women
- •*Women of child-bearing potential unless they use effective contraception
- •Other protocol-defined exclusion criteria may apply. Please refer to the protocol.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate clear skin effect in patients with plaque psoriasis.Plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858EUCTR2015-003701-42-LTovartis Pharma Services AG1,615
进行中（未招募）
1 期
A study to evaluate clear skin effect in patients with plaque psoriasis.Plaque psoriasisEUCTR2015-003701-42-ESovartis Farmacéutica, S.A.1,615
进行中（未招募）
1 期
A study to evaluate clear skin effect in patients with plaque psoriasis.MedDRA version: 18.1 Level: LLT Classification code 10050576 Term: Psoriasis vulgaris System Organ Class: 100000004858Plaque psoriasisEUCTR2015-003701-42-PTovartis Pharma Services AG1,660
进行中（未招募）
1 期
A study to evaluate clear skin effect in patients with plaque psoriasis.MedDRA version: 18.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858Plaque psoriasisEUCTR2015-003701-42-BEovartis Pharma Services AG1,615
进行中（未招募）
1 期
A study to evaluate clear skin effect in patients with plaque psoriasis.MedDRA version: 18.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 100000004858Plaque psoriasisEUCTR2015-003701-42-GBovartis Pharma Services AG1,615